IPO boom: An­ti­body ex­perts at Gen­mab out­line glob­al am­bi­tion in pitch for $500M

Gen­mab has made a name — and some de­cent mon­ey — for it­self as the heavy­weight part­ner of J&J that came up with the block­buster Darza­lex (dara­tu­mum­ab). But for the Copen­hagen-based biotech, it’s just the be­gin­ning of a jour­ney to be­come an in­ter­na­tion­al­ly ac­claimed play­er in an­ti­body-based can­cer ther­a­pies.

The com­pa­ny laid out its vi­sion in a fil­ing for a whop­ping $500 mil­lion IPO late Tues­day, un­equiv­o­cal­ly stat­ing that it plans to launch its own pro­pri­etary prod­uct — one it owns at least 50% of — by 2025. And there are at least five of these in the pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER